CD226 and non-small cell lung carcinoma: In addition, CD226 expression is associated with clinical outcomes in patients with NSCLC treated with an anti-PD-L1 antibody, and PD-1 reduces phosphorylation of both CD226 and CD28 via its ITIM-containing intracellular domain (ICD) [107].